Shams ul Nisa

Citi Pharma Limited (CPHL) is advancing its expansion plans, showing strong growth in both its Active Pharmaceutical Ingredient (API) and Formulation segments, reports WealthPk.Citi Pharma Limited successfully conducted an IPO to fund its expansion plans, directing investments toward key areas including Active Pharmaceutical Ingredients (API), Formulation, and a planned Hospital Facility. The company has made significant strides in utilizing these funds to drive growth and enhance its position in the pharmaceutical industry.

Established on October 08, 2012, the company specializes in the manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. Additionally, Citi Pharma Limited has completed the civil work for expanding its paracetamol production and developing a new multi-purpose Active Pharmaceutical Ingredient (API) facility capable of producing Ascorbic Acid, Chloroquine Phosphate, and Hydroxychloroquine Phosphate.

Moreover, it has completed work on its Cephalosporin facility by the company’s in-house engineering team. The company has also acquired essential equipment, including boilers and fluid bed dryers, to support its API segment, which is projected to grow at a five-year CAGR of 13% from FY23 to FY27. The company has acquired key equipment to enhance production capabilities, including clean rooms for machinery, vial filling and stoppering machines, high-performance liquid chromatography (HPLC) systems, vial capping machines, automated capsule filling machines, rotary tablet press machines, and advanced lab equipment.

These developments mark a major step in Citi Pharma’s efforts to strengthen its formulation capabilities and expand its pharmaceutical offerings. In addition, Citi Pharma has partnered with Indonesian pharmaceutical company Mersi Farma to establish advanced API manufacturing facilities in Indonesia. This collaboration, which includes a Paracetamol API plant with an annual production capacity of 10,000 metric tons and an Amoxicillin API plant with a capacity of 1,800 metric tons, is expected to strengthen Citi Pharma’s global footprint in pharmaceutical manufacturing.

Despite some delays in establishing its hospital facility, Citi Pharma Limited has secured land at DHA Rahbar, Raiwind Road, Lahore, ensuring a more suitable location that complies with regulatory requirements. The company is actively expanding its Active Pharmaceutical Ingredient (API) and Formulation segments through substantial investments in infrastructure and advanced equipment. These efforts aim to strengthen the company’s manufacturing capabilities and drive long-term growth. It can be seen that Citi Pharma’s commitment is to expand globally and explore international market opportunities.

Credit: INP-WealthPk